Adcendo and Multitude target cancer resistance to ADCs in $1BN deal

As antibody-drug conjugates (ADCs) continue to heat up in the industry, Adcendo of Denmark has gained the global rights from Multitude Therapeutics to develop the Chinese companyâs ADC for the treatment of cancer outside of the Greater China region.